Akifumi Morinaka

JAFCO Group Co. Ltd. (JAFCO Group) is the private equity arm of the parent firm, JAFCO (TSE: 8595), founded in 1973. The firm is headquartered in Tokyo, Japan.

Rege Nephro Co. Ltd. is a company based in Kyoto, Japan that specializes in the research, development, production, and sales of renal disease treatment drugs. The Japanese company has developed a unique and realistic approach to induce high-efficiency differentiation from stem cells, with the aim of saving patients suffering from renal failure. The company's research and development activities focus on developing various solutions for renal disease and improving the quality of life of patients suffering from renal disease. Rege Nephro Co. was founded in 2019 by Kenji Nagafune.

Chordia Therapeutics, Inc. engages in the research and development of novel therapies for cancers. It handles research and development of low-molecular-weight drugs with unprecedented new mechanisms of action in the oncology area. The company was founded by Hiroshi Miyake and Daisuke Morishita on October 12, 2017 and is headquartered in Fujisawa, Japan.